Iterum Therapeutics plc (ITRMF) Net Cash Flow (2017 - 2025)

Iterum Therapeutics' Net Cash Flow history runs 9 years deep, the most recent figure standing at -$2.0 million for Q3 2025.

• In Q3 2025, Net Cash Flow fell 123.97% year-over-year to -$2.0 million; the TTM figure through Sep 2025 stood at -$2.4 million (down 127.51% YoY), while the FY2024 annual figure was $18.1 million, up 221.18% from the prior year.
• Net Cash Flow for Q3 2025 stood at -$2.0 million, down from $369000.0 in the prior quarter.
• The five-year high for Net Cash Flow was $51.9 million in Q1 2021, with the low at -$30.1 million in Q2 2021.
• The 5-year median for Net Cash Flow is -$1.2 million (2022), against an average of -$188578.9.
• The sharpest annual moves came in 2024 and 2025: Net Cash Flow surged 744.84% in 2024, then slumped 951.3% in 2025.
• Iterum Therapeutics' Net Cash Flow stood at -$8.6 million in 2021, then jumped by 106.38% to $546000.0 in 2022, then jumped by 132.42% to $1.3 million in 2023, then surged by 744.84% to $10.7 million in 2024, then sank by 118.91% to -$2.0 million in 2025.
• Business Quant data shows ITRMF's Net Cash Flow at -$2.0 million in Q3 2025, $369000.0 in Q2 2025, and -$11.4 million in Q1 2025.